The selective prolyl hydroxylase inhibitor IOX5 stabilizes HIF-1α and compromises development and progression of acute myeloid leukemia

The selective prolyl hydroxylase inhibitor IOX5 stabilizes HIF-1α and compromises development and progression of acute myeloid leukemia

<p>Acute myeloid leukemia (AML) is a largely incurable disease, for which new treatments are urgently needed. While leukemogenesis occurs in the hypoxic bone marrow, the therapeutic tractability of the hypoxia-inducible factor (HIF) system remains undefined. Given that inactivation of HIF-1&am...

Full description

Bibliographic Details
Main Authors: Lawson, H, Holt-Martyn, JP, Dembitz, V, Kabayama, Y, Wang, LM, Bellani, A, Atwal, S, Saffoon, N, Durko, J, van de Lagemaat, LN, De Pace, AL, Tumber, A, Corner, T, Salah, E, Arndt, C, Brewitz, L, Bowen, M, Dubusse, L, George, D, Allen, L, Guitart, AV, Fung, TK, So, CWE, Schwaller, J, Gallipoli, P, O'Carroll, D, Schofield, CJ, Kranc, KR
Format: Journal article
Language:English
Published: Springer Nature 2024

Similar Items